English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 55224/89525 (62%)
造訪人次 : 10724389      線上人數 : 20
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library & TKU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://tkuir.lib.tku.edu.tw:8080/dspace/handle/987654321/109463


    題名: No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment
    作者: Hung, Tsung-Hsing;Tsai, Chen-Chi;Tseng, Chih-Wei;Tseng, Kuo-Chih;Hsieh, Yu-Hsi;Tsai, Chih-Chun
    關鍵詞: esophageal variceal bleeding;renal function impairment;somatostatin;terlipressin
    日期: 2016-11
    上傳時間: 2017-02-21 02:10:31 (UTC+8)
    摘要: Objective
    To study the differences in mortality between terlipressin and somatostatin treatments in cirrhotic patients with esophageal variceal bleeding (EVB) and renal functional impairment (RFI).

    Methods
    The National Health Insurance Database, part of the Taiwan National Health Insurance Program, was used to enroll cirrhotic patients who had received endoscopic variceal ligation plus somatostatin or terlipressin for EVB and who were hospitalized between 1 January 2007 and 31 December 2010. The differences in mortality between the two vasoactive agents were compared and the risk factors for 30-day mortality because of EVB were identified.

    Results
    A total of 2324 cirrhotic patients with EVB were enrolled. The 30-day mortality data showed no significant differences between the somatostatin and the terlipressin groups (P=0.232). The risk of 30-day mortality was significantly higher in male patients [hazard ratio (HR): 1.50, P=0.002] and patients with hepatic encephalopathy (HR: 1.82, P<0.001), ascites (HR: 1.32, P=0.008), bacterial infections (HR: 2.10, P<0.001), hepatocellular carcinoma (HR: 2.09, P<0.001), and RFI (HR: 3.89, P<0.001). A subgroup analysis of cirrhotic patients with RFI was carried out. The overall 30-day mortality was higher in patients treated with somatostatin than in those treated with terlipressin (52.6 vs. 42.3%), but the difference failed to reach significance (adjust HR: 1.49, 95% confidence interval: 0.94–2.37, P=0.091).

    Conclusion
    RFI was the most important risk factor for 30-day mortality in EVB patients. Terlipressin and somatostatin had similar effects on 30-day mortality in cirrhotic patients with EVB and RFI.
    關聯: European Journal of Gastroenterology & Hepatology 28(11), p.1275–1279
    DOI: 10.1097/MEG.0000000000000703
    顯示於類別:[數學學系暨研究所] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    index.html0KbHTML183檢視/開啟
    No Difference in Mortality between Terlipressin and Somatostatin Treatments in Cirrhotic Patients with Esophageal Variceal Bleeding and Renal Functional Impairment.pdf288KbAdobe PDF0檢視/開啟

    在機構典藏中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library & TKU Library IR teams. Copyright ©   - 回饋